These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 1588042)

  • 1. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
    Lamb CA; Cresswell P
    J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.
    Roche PA; Marks MS; Cresswell P
    Nature; 1991 Dec; 354(6352):392-4. PubMed ID: 1956401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
    Khalil H; Brunet A; Thibodeau J
    J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DR alpha beta dimers released from complexes with invariant chain fail to stimulate alloreactive T cell clones.
    Demotz S
    Eur J Immunol; 1993 Sep; 23(9):2100-8. PubMed ID: 8370392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.
    Newcomb JR; Cresswell P
    J Immunol; 1993 Jan; 150(2):499-507. PubMed ID: 8419482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain.
    Busch R; Vturina IY; Drexler J; Momburg F; Hämmerling GJ
    Eur J Immunol; 1995 Jan; 25(1):48-53. PubMed ID: 7843252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain.
    Arunachalam B; Lamb CA; Cresswell P
    Int Immunol; 1994 Mar; 6(3):439-51. PubMed ID: 8186195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo.
    Newcomb JR; Cresswell P
    J Immunol; 1993 Oct; 151(8):4153-63. PubMed ID: 8409392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia.
    Veenstra H; Jacobs P; Dowdle EB
    Cell Immunol; 1996 Jul; 171(1):68-73. PubMed ID: 8660839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural analysis of invariant chain subsets as a function of their association with MHC class II chains.
    Nguyen QV; Reyes VE; Humphreys RE
    Arch Biochem Biophys; 1995 Feb; 317(1):128-32. PubMed ID: 7872774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
    Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
    J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assembly of major histocompatibility complex class II subunits with invariant chain.
    Neumann J; Koch N
    FEBS Lett; 2005 Nov; 579(27):6055-9. PubMed ID: 16242130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
    Riberdy JM; Newcomb JR; Surman MJ; Barbosa JA; Cresswell P
    Nature; 1992 Dec; 360(6403):474-7. PubMed ID: 1448172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular transport of class II MHC molecules directed by invariant chain.
    Lotteau V; Teyton L; Peleraux A; Nilsson T; Karlsson L; Schmid SL; Quaranta V; Peterson PA
    Nature; 1990 Dec; 348(6302):600-5. PubMed ID: 2250716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invariant chain influences post-translational processing of HLA-DR molecules.
    Schaiff WT; Hruska KA; Bono C; Shuman S; Schwartz BD
    J Immunol; 1991 Jul; 147(2):603-8. PubMed ID: 2071896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.